Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, Lexington, MA.
Int J Cancer. 2015 Nov 15;137(10):2424-31. doi: 10.1002/ijc.29601. Epub 2015 Jul 15.
Non-steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid (aspirin) have been associated with a reduced risk for certain cancers. We explored the association between use of NSAIDs and the risk of head and neck cancer (HNC). We conducted a case-control analysis in the UK-based Clinical Practice Research Datalink (CPRD) among people below the age of 90 years with incident HNC between 1995 and 2013. Six controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the CPRD prior to the HNC diagnosis. Other potential confounders including comorbidities and comedication were also evaluated, and we adjusted our final analyses for BMI, smoking and alcohol consumption. Our analyses included 2,745 HNC cases and 16,470 controls. Aspirin or NSAID use overall did not significantly change the HNC risk. However, patients with six or more prescriptions for ibuprofen were at a statistically significantly reduced risk for HNC (adjusted OR 0.59, 95% CI 0.37-0.94). The HNC risk tended to decrease with increasing cumulative exposure to ibuprofen, and to be more pronounced for cancer of the larynx. To conclude, in this large population-based observational study we found a decreased risk for HNC associated with regular use of ibuprofen.
非甾体抗炎药（NSAIDs）和乙酰水杨酸（阿司匹林）与某些癌症的风险降低有关。我们探讨了 NSAIDs 的使用与头颈部癌症（HNC）风险之间的关联。我们在英国临床实践研究数据链接（CPRD）中进行了一项病例对照分析，纳入了 1995 年至 2013 年间年龄在 90 岁以下、患有 HNC 的患者。每个病例匹配 6 名对照，匹配因素包括年龄、性别、日历时间、全科医生和在 HNC 诊断前在 CPRD 中活跃的年数。还评估了其他潜在混杂因素，包括合并症和合并用药，并对我们的最终分析进行了 BMI、吸烟和饮酒情况的调整。我们的分析包括 2745 例 HNC 病例和 16470 例对照。总体而言，阿司匹林或 NSAIDs 的使用并未显著改变 HNC 的风险。然而，使用布洛芬处方六次或更多次的患者 HNC 风险显著降低（调整后的 OR 0.59，95%CI 0.37-0.94）。HNC 风险随着累积暴露于布洛芬的增加而降低，且在喉癌中更为明显。总之，在这项大型基于人群的观察性研究中，我们发现常规使用布洛芬与 HNC 风险降低相关。
